These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1715 related articles for article (PubMed ID: 25283629)
21. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120 [TBL] [Abstract][Full Text] [Related]
22. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333 [TBL] [Abstract][Full Text] [Related]
23. The pathological characteristics of glioma stem cell niches. He H; Li MW; Niu CS J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090 [TBL] [Abstract][Full Text] [Related]
24. Differential expression of stem cell markers in proliferating cells in glioma. Rehfeld M; Matschke J; Hagel C; Willenborg K; Glatzel M; Bernreuther C J Cancer Res Clin Oncol; 2021 Oct; 147(10):2969-2982. PubMed ID: 34170383 [TBL] [Abstract][Full Text] [Related]
25. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864 [TBL] [Abstract][Full Text] [Related]
26. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors. Sabet MN; Rakhshan A; Erfani E; Madjd Z Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000 [TBL] [Abstract][Full Text] [Related]
27. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance. Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857 [TBL] [Abstract][Full Text] [Related]
28. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma. Lvu W; Fei X; Chen C; Zhang B Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165 [TBL] [Abstract][Full Text] [Related]
29. Survival and low-grade glioma: the emergence of genetic information. Claus EB; Walsh KM; Wiencke JK; Molinaro AM; Wiemels JL; Schildkraut JM; Bondy ML; Berger M; Jenkins R; Wrensch M Neurosurg Focus; 2015 Jan; 38(1):E6. PubMed ID: 25552286 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis. Han M; Guo L; Zhang Y; Huang B; Chen A; Chen W; Liu X; Sun S; Wang K; Liu A; Li X Mol Neurobiol; 2016 Jan; 53(1):720-727. PubMed ID: 25589004 [TBL] [Abstract][Full Text] [Related]
32. A multivariate retrospective analysis of high-grade gliomas: Survival and prognostic factors. Shi W; Wang X; Liu S; Zheng Z; Dong L; Jiang X Cancer Med; 2024 Aug; 13(15):e7456. PubMed ID: 39118481 [TBL] [Abstract][Full Text] [Related]
33. The relationship among integrin alpha 7, CD133 and Nestin as well as their correlation with clinicopathological features and prognosis in astrocytoma patients. Li C; Liu J; Yang W; Chen C; Wu B Clin Neurol Neurosurg; 2022 Jun; 217():107198. PubMed ID: 35430343 [TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. Wu X; Wu F; Xu D; Zhang T J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925 [TBL] [Abstract][Full Text] [Related]
35. Diagnostic challenges, management and outcomes of midline low-grade gliomas. Waqar M; Hanif S; Rathi N; Das K; Zakaria R; Brodbelt AR; Walker C; Jenkinson MD J Neurooncol; 2014 Nov; 120(2):389-98. PubMed ID: 25096797 [TBL] [Abstract][Full Text] [Related]
36. High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. Hatanpaa KJ; Hu T; Vemireddy V; Foong C; Raisanen JM; Oliver D; Hiemenz MC; Burns DK; White CL; Whitworth LA; Mickey B; Stegner M; Habib AA; Fink K; Maher EA; Bachoo RM J Neurooncol; 2014 Mar; 117(1):183-189. PubMed ID: 24519516 [TBL] [Abstract][Full Text] [Related]
37. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
38. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Hang D; Dong HC; Ning T; Dong B; Hou DL; Xu WG Dis Esophagus; 2012; 25(7):638-44. PubMed ID: 22236447 [TBL] [Abstract][Full Text] [Related]
40. Tenascin-C: a novel candidate marker for cancer stem cells in glioblastoma identified by tissue microarrays. Nie S; Gurrea M; Zhu J; Thakolwiboon S; Heth JA; Muraszko KM; Fan X; Lubman DM J Proteome Res; 2015 Feb; 14(2):814-22. PubMed ID: 25469866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]